top of page

Flamma Group, back from China

In the early 2000s Flamma relocated from Bergamo to Dalian - Liaoning - province of China. And that she is now ready to return to her homeland.

The company, leader in the production of active and intermediate ingredients for the pharmaceutical industry, has chosen to reshor, or to bring part of its production organization back to Lombardy - Italy.

Last April Flamma completed the closing for the acquisition from Teva (an Israeli pharmaceutical giant) of the Sicor Bulciago production site, in the province of Lecco.

The operation made it possible to save all 62 jobs that had been endangered by the crisis experienced by the Israeli company, forced over the years to carry out substantial downsizing, including closures and layoffs.

Bulciago, a few kilometers from the border with Bergamo and located right along the Briantea, has thus become the third production site of Flamma in Italy, after those of Chignolo and Isso, and is now close to restarting the business in September, initially with 44 employees of the former Sicor.

"Potentially the plant can also employ 150 qualified profiles, an important employment prospect after the difficulties of recent years, but it will still have to deal with the dizzying increase in electricity costs, which despite a constantly growing turnover they will lead to a reduction in margins ”, are the words of the group's CEO, Gianpaolo Negrisoli, reported by Corriere Economica.

The Lecco plant will reopen on 10 September. It has a production capacity of 600 cubic meters of reaction and is able to recover 95% of the solvents used, a green turning point and with a view to a circular economy which can no longer be ignored.

The Bergamo-based company, which has a turnover of over 121 million euros, is also present in the United States, in addition of course to China. Where, announced Negrisoli, Flamma intends to double the plant.

In the recent history of the Italian group there are products such as the active ingredient of Polase or the generic of Aulin. And customers of the caliber of Gilead, which has launched drugs on the market capable of eradicating hepatitis C.

For Covid, on the other hand, Flamma worked on the development of Remdesivir.

A large Italian group that returns from China to Italy, without however abandoning the Asian market.

source: 08/09/2022 Filippo Merli


bottom of page